

CLAIMS

We Claim:

1. A drug delivery system for controlled protein release into a biological environment comprising:

- 5 a) a sparingly soluble biocompatible particle;
- b) an effective amount of a protein or peptide deposited onto the particle forming a substantially insoluble protein-particle combination; and
- c) a biocompatible polymeric matrix having dispersed
10 therein the protein-particle combination.

2. The drug delivery system of claim 1 wherein the protein-particle combination has a biocompatible particle to protein or peptide ratio from about 1:10 to 100,000:1 by weight.
15

3. The drug delivery system of claim 1 wherein the protein-particle combination has a biocompatible particle to protein or peptide ratio from about 1:10 to 1000:1 by weight.

20 4. The drug delivery system of claim 1 wherein the protein-particle combination is present in relation to polymeric matrix at from about 0.01 to 30% by weight.

5. The drug delivery system of claim 1 wherein said biocompatible particle is a sparingly soluble salt or oxide selected from the group consisting of zinc salts, zinc oxides, magnesium salts, magnesium oxides, calcium salts, and calcium oxides.

6. The drug delivery system of claim 1 wherein said biocompatible particle is selected from the group consisting of zinc carbonate, zinc oxide, zinc tartrate, zinc hydroxide, zinc phosphate, zinc citrate, magnesium oxide, magnesium hydroxide, magnesium carbonate, calcium oxide, calcium phosphate, calcium sulfate, calcium carbonate, and combinations thereof.

7. The drug delivery system of claim 1 wherein said protein or peptide is selected from the group consisting of oxytocin, vasopressin, adrenocorticotrophic hormone, epidermal growth factor, platelet-derived growth factor (PDGF), prolactin, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH agonists, growth hormone, growth hormone releasing factor, insulin, erythropoietin, somatostatin, glucagon, interleukin (including IL-2, IL-11, IL-12, etc.), interferon- α , interferon- β ,

interferon- γ , gastrin, tetragastrin, pentagastrin, urogastrone,
secretin, calcitonin, enkephalins, endorphins, angiotensins,
thyrotropin releasing hormone (TRH), tumor necrosis factor
(TNF), parathyroid hormone (PTH), nerve growth factor (NGF),
5 granulocyte-colony stimulating factor (G-CSF), granulocyte
macrophage-colony stimulating factor (GM-CSF), macrophage-colony
stimulating factor (M-CSF), heparinase, vascular endothelial
growth factor (VEG-F), bone morphogenic protein (BMP), hANP,
glucagon-like peptide (GLP-1), renin, bradykinin, bacitracins,
10 polymyxins, colistins, tyrocidine, gramicidins, cyclosporins,
enzymes, cytokines, antibodies, vaccines, antibiotics,
antibodies, glycoproteins, and combinations thereof.

8. The drug delivery system of claim 1 wherein said
15 protein is selected from the group consisting of human growth
hormone and insulin.

9. The drug delivery system of claim 1 wherein said
biocompatible polymeric matrix is selected from the group
20 consisting of polymeric particles, implants, microcapsules,
microspheres, nanospheres, polymeric gels, environment
responsive polymers or gels, and combinations thereof.

10. The drug delivery system of claim 1 wherein said biocompatible polymeric matrix is comprised of a polymer or gel material selected from the group consisting of nondegradable
5 polymers, biodegradable polymers, absorbable polymers, bioerodible polymers, block copolymers, and combinations thereof.

11. The drug delivery system of claim 10 wherein said
10 biocompatible polymeric matrix is comprised of a biodegradable polymer selected from the group consisting of poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, polyanhydrides, poly(ortho ester)s, poly(ϵ -caprolactone),
15 poly(hydroxybutyric acid), polyaminoacids, and blends and copolymers thereof.

12. The drug delivery system of claim 10 wherein said biocompatible polymeric matrix is a block copolymer selected
20 from the group consisting of A-B-A block copolymers, B-A-B block copolymers, A-B block copolymers, and combinations thereof, and wherein said A block is a biodegradable polymer selected from

the group consisting of poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, polyanhydrides, poly(ϵ -caprolactone)s, poly(hydroxybutyric acid)s, 5 poly(aminoacids)s, poly(ortho ester)s, and blends and copolymers thereof, and said B block is polyethylene glycol.

13. The drug delivery system of claim 10 wherein said biocompatible polymeric matrix is comprised of a nondegradable polymer selected from the group consisting of polyacrylates, polyacrylate esters, silicone rubbers, poloxamers, tetronics, polyethylenes, poly(methyl methacrylate)s, polymethyl methacrylate esters, polystyrenes, ethylene-vinyl acetate copolymers, polyethylene-maleic anhydride copolymers, 15 polyamides, polymers of ethylene-vinyl acetates, acyl substituted cellulose acetates, nondegradable polyurethanes, poly(vinyl chloride)s, poly(vinyl fluoride)s, poly(vinyl imidazole)s, chlorosulphonate polyolefins, poly(ethylene oxide)s, and blends and copolymers thereof.

20

14. The drug delivery system of claim 1 wherein the protein or peptide is deposited onto a surface of the particle.

15. The drug delivery system of claim 1 wherein a plurality of protein or peptide molecules are present, a first portion of said plurality of protein or peptide molecules are deposited on the particle and dispersed within the polymeric matrix, and a second portion of said plurality of protein or peptide molecules are dispersed within the polymeric matrix.

16. The drug delivery system of claim 1 further comprising a second protein or peptide.

17. The drug delivery system of claim 16 wherein the second protein or peptide is deposited on the particle dispersed within the polymeric matrix.

18. The drug delivery system of claim 16 wherein the second protein or peptide is dispersed within the polymeric matrix.

19. The drug delivery system of claim 16 wherein a plurality of second protein or peptide molecules are present, a first portion of said plurality of second protein or peptide molecules are deposited on the particle and dispersed within the

polymeric matrix, and a second portion of said plurality of second protein or peptide molecules are dispersed within the polymeric matrix.

5 20. A method for controlled delivery of a protein to a warm-blooded animal comprising:

- B
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
- a) depositing a protein or peptides onto a sparingly soluble biocompatible particle to form a protein-particle combination;
 - b) loading the protein-particle combination in a biocompatible polymeric matrix; and
 - c) administering the loaded biocompatible polymeric matrix to a warm-blooded animal.

21. The method of claim 20 wherein the protein-particle combination has a biocompatible particle to protein or peptide ratio from about 1:10 to 100,000:1 by weight.

22. The method of claim 20 wherein the protein-particle combination has a biocompatible particle to protein or peptide ratio from about 1:10 to 1000:1 by weight.

23. The method of claim 20 wherein the protein-particle combination is present in relation to polymeric matrix at from about 0.01 to 30% by weight.

5 24. The method of claim 20 wherein the loaded biocompatible polymeric matrix is delivered by a route selected from the group consisting of parenteral, ocular, topical, implantation, inhalation, vaginal, buccal, transmucosal, transurethral, rectal, nasal, pulmonary, and combinations
B
10 thereof.

25. The method of claim 24 wherein the route of administration is parenteral.

15 26. The method of claim 20 wherein said biocompatible particle is a sparingly soluble salt or oxide selected from the group consisting of zinc salts, zinc oxides, magnesium salts, magnesium oxides, calcium salts, and calcium oxides.

20 27. The method of claim 20 wherein said sparingly soluble particle is selected from the group consisting of zinc carbonate, zinc oxide, zinc tartrate, zinc hydroxide, zinc

phosphate, zinc citrate, magnesium oxide, magnesium hydroxide, magnesium carbonate, calcium oxide, calcium phosphate, calcium sulfate, calcium carbonate, and combinations thereof.

5 28. The method of claim 20 wherein said protein or peptide
is selected from the group consisting of oxytocin, vasopressin,
adrenocorticotrophic hormone, epidermal growth factor, platelet-
derived growth factor (PDGF), prolactin, luteinizing hormone
releasing hormone (LHRH), LHRH agonists, LHRH agonists, growth
hormone, growth hormone releasing factor, insulin,
erythropoietin, somatostatin, glucagon, interleukin (including
IL-2, IL-11, IL-12, etc.), interferon- α , interferon- β ,
interferon- γ , gastrin, tetragastrin, pentagastrin, urogastrone,
secretin, calcitonin, enkephalins, endorphins, angiotensins,
thyrotropin releasing hormone (TRH), tumor necrosis factor
(TNF), parathyroid hormone (PTH), nerve growth factor (NGF),
granulocyte-colony stimulating factor (G-CSF), granulocyte
macrophage-colony stimulating factor (GM-CSF), macrophage-colony
stimulating factor (M-CSF), heparinase, vascular endothelial
20 growth factor (VEG-F), bone morphogenic protein (BMP), hANP,
glucagon-like peptide (GLP-1), renin, bradykinin, bacitracins,
polymyxins, colistins, tyrocidine, gramicidins, cyclosporins,

enzymes, cytokines, antibodies, vaccines, antibiotics,
antibodies, glycoproteins, and combinations thereof.

29. The method of claim 20 wherein said protein is
5 selected from the group consisting of human growth hormone and
insulin.

B¹
30. The method of claim 20 wherein said biocompatible
polymeric matrix is selected from the group consisting of
10 polymeric particles, implants, microcapsules, microspheres,
nanospheres, polymeric gels, environment responsive polymers or
gels, and combinations thereof.

31. The method of claim 20 wherein said biocompatible
15 polymeric matrix is comprised of a polymer material selected
from the group consisting of nondegradable polymers,
biodegradable polymers, absorbable polymers, bioerodible
polymers, block copolymers, and combinations thereof.

20 32. The method of claim 31 wherein said biocompatible
polymeric matrix is comprised of a biodegradable polymer
selected from the group consisting of poly(lactide)s,

poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, polyanhydrides, poly(ortho ester)s, poly(ϵ -caprolactone), poly(hydroxybutyric acid), polyaminoacids, and blends and
5 copolymers thereof.

33. The method of claim 31 wherein said biocompatible polymeric matrix is a block copolymer selected from the group consisting of A-B-A block copolymers, B-A-B block copolymers, A-B block copolymers, and combinations thereof, and wherein said A block is a biodegradable polymer selected from the group consisting of poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, polyanhydrides, polycaprolactones, poly(ϵ -caprolactone)s, poly(hydroxybutyric acid)s, poly(aminoacids)s, poly(ortho ester)s, and blends and
10
15
copolymers thereof, and said B block is polyethylene glycol.

34. The method of claim 31 wherein said biocompatible
20 polymeric matrix is comprised of a nondegradable polymer selected from the group consisting of polyacrylates, polyacrylate esters, silicone rubbers, poloxamers, tetronics,

polyethylenes, poly(methyl methacrylate)s, polymethyl
methacrylate esters, polystyrenes, ethylene-vinyl acetate
copolymers, polyethylene-maleic anhydride copolymers,
polyamides, polymers of ethylene-vinyl acetates, acyl
5 substituted cellulose acetates, nondegradable polyurethanes,
poly(vinyl chloride)s, poly(vinyl fluoride)s, poly(vinyl
imidazole)s, chlorosulphonate polyolefins, poly(ethylene
oxide)s, and blends and copolymers thereof.

10 35. The method of claim 20 wherein a plurality of protein
or peptide molecules are present, a first portion of said
plurality of protein or peptide molecules are deposited on the
particle and dispersed within the polymeric matrix, and a second
portion of said plurality of protein or peptide molecules are
15 dispersed within the polymeric matrix.

36. The method of claim 20 further comprising a second
protein or peptide.

20 37. The method of claim 36 wherein the second protein or
peptide is deposited on the particle dispersed within the
polymeric matrix.

38. The method of claim 36 wherein the second protein or peptide is dispersed within the polymeric matrix.

5 39. The method of claim 36 wherein a plurality of second protein or peptide molecules are present, a first portion of said plurality of second protein or peptide molecules are deposited on the particle and dispersed within the polymeric matrix, and a second portion of said plurality of second protein or peptide molecules are dispersed within the polymeric matrix.

10 40. A method of preparing a protein delivery system comprising:

15 a) depositing a protein or peptide onto a sparingly soluble biocompatible particle to form a protein-particle combination; and

b) loading the protein-particle combination in a biocompatible polymeric matrix.

20 41. The method of claim 40 wherein the protein-particle combination has a biocompatible particle to protein or peptide ratio from about 1:10 to 100,000:1 by weight.

15
17 42. The method of claim 40 wherein the protein-particle combination has a biocompatible particle to protein or peptide ratio from about 1:10 to 1000:1 by weight.

5
18 43. The method of claim 40 wherein the protein-particle combination is present in relation to polymeric matrix at from about 0.01 to 30% by weight.

10
19 44. The method of claim 40 wherein the protein or peptide is deposited onto the particle by a mechanism selected from the group consisting of adsorption, absorption, and coprecipitation.

15
20 45. The method of claim 40 wherein the protein or peptide is deposited onto a surface of the particle.

21 46. The method of claim 40 wherein said biocompatible particle is a sparingly soluble salt or oxide selected from the group consisting of zinc salts, zinc oxides, magnesium salts, magnesium oxides, calcium salts, and calcium oxides.

22 47. The method of claim 40 wherein said sparingly soluble particle is selected from the group consisting of zinc carbonate, zinc oxide, zinc tartrate, zinc hydroxide, zinc phosphate, zinc citrate, magnesium oxide, magnesium hydroxide, magnesium carbonate, calcium oxide, calcium phosphate, calcium sulfate, calcium carbonate, and combinations thereof.

48. The method of claim 30 wherein said protein or peptide is selected from the group consisting of oxytocin, vasopressin, adrenocorticotrophic hormone, epidermal growth factor, platelet-derived growth factor (PDGF), prolactin, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH agonists, growth hormone, growth hormone releasing factor, insulin, erythropoietin, somatostatin, glucagon, interleukin (including IL-2, IL-11, IL-12, etc.), interferon- α , interferon- β , interferon- γ , gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), parathyroid hormone (PTH), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), heparinase, vascular endothelial

growth factor (VEG-F), bone morphogenic protein (BMP), hANP,
glucagon-like peptide (GLP-1), renin, bradykinin, bacitracins,
polymyxins, colistins, tyrocidine, gramicidins, cyclosporins,
enzymes, cytokines, antibodies, vaccines, antibiotics,
5 antibodies, glycoproteins, and combinations thereof.

24 15 49. The method of claim 40 wherein said protein is
selected from the group consisting of human growth hormone and
insulin.

25 15 50. The method of claim 40 wherein said biocompatible
polymeric matrix is selected from the group consisting of
polymeric particles, implants, microcapsules, microspheres,
nanospheres, polymeric gels, environment responsive polymers or
15 gels, and combinations thereof.

26 15 51. The method of claim 40 wherein said biocompatible
polymeric matrix is comprised of a polymer material selected
from the group consisting of nondegradable polymers,
20 biodegradable polymers, absorbable polymers, bioerodible
polymers, block copolymers, and combinations thereof.

27 52. The method of claim 51 wherein said biocompatible
polymeric matrix is comprised of a biodegradable polymer

selected from the group consisting of poly(lactide)s,
poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic
5 acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic
acid)s, polyanhydrides, poly(ortho ester)s, poly(ε-caprolactone),
poly(hydroxybutyric acid), polyaminoacids, and blends and
copolymers thereof.

28 53. The method of claim 51 wherein said biocompatible
polymeric matrix is a block copolymer selected from the group
consisting of A-B-A block copolymers, B-A-B block copolymers, A-
B block copolymers, and combinations thereof, and wherein said A
block is a biodegradable polymer selected from the group
15 consisting of poly(lactide)s, poly(glycolide)s,
poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic
acid)s, poly(lactic acid-co-glycolic acid)s, polyanhydrides,
poly(ε-caprolactone)s, poly(hydroxybutyric acid)s,
poly(aminoacids)s, poly(ortho ester)s, and blends and copolymers
20 thereof, and said B block is polyethylene glycol.

26

29/ 54. The method of claim 51 wherein said biocompatible
polymeric matrix is comprised of a nondegradable polymer
selected from the group consisting of polyacrylates,
polyacrylate esters, silicone rubbers, poloxamers, tetronics,
5 polyethylenes, poly(methyl methacrylate)s, polymethyl
methacrylate esters, polystyrenes, ethylene-vinyl acetate
copolymers, polyethylene-maleic anhydride copolymers,
polyamides, polymers of ethylene-vinyl acetates, acyl
substituted cellulose acetates, nondegradable polyurethanes,
10 poly(vinyl chloride)s, poly(vinyl fluoride)s, poly(vinyl
imidazole)s, chlorosulphonate polyolefins, poly(ethylene
oxide)s, and blends and copolymers thereof.

30/ 55. A drug delivery system for controlled protein release
15 into a biological environment comprising:

a) a sparingly soluble biocompatible particle selected from
the group consisting of zinc salts, zinc oxides, magnesium
salts, magnesium oxides, calcium salts, calcium oxides, and
combinations thereof;

20 b) an effective amount of a protein or peptide deposited
onto the particle forming a substantially insoluble protein-
particle combination, wherein the protein-particle combination

has a biocompatible particle to protein or peptide ratio from about 1:10 to 100,000:1 by weight; and

c) a biocompatible polymeric matrix having dispersed therein the protein-particle combination, wherein the protein-particle combination is present in relation to polymeric matrix at from about 0.01 to 30% by weight.

31 56. A drug delivery system for controlled protein release into a biological environment comprising:

- 10 a) a sparingly soluble biocompatible particle;
- b) an effective amount of a protein or peptide deposited onto the particle forming a substantially insoluble protein-particle combination; and
- 15 c) a biocompatible polymeric matrix said comprised of a polymer or gel material selected from the group consisting of nondegradable polymers, biodegradable polymers, absorbable polymers, bioerodible polymers, block copolymers, and combinations thereof, said polymeric matrix in a form selected from the group consisting of polymeric particles, implants,
- 20 microcapsules, microspheres, nanospheres, polymeric gels, environment responsive polymers or gels, and combinations

thereof, said polymeric matrix having dispersed therein the protein-particle combination.

5

10
11
12
13
14
15
16
17
18
19
20

20

Thorpe, North & Western
8180 South 700 East, Suite #200
Sandy, UT 84070
(801) 566-6633

52

Docket No. T8418.NP
Serial No. 09/827,100

9

AMENDMENT (marked-up version)

Please cancel claim 48.

Please add new claim 57 as follows: ⁵

²³ ~~47~~. (New) The method of claim ~~40~~ wherein said protein or peptide is selected from the group consisting of oxytocin, vasopressin, adrenocorticotrophic hormone, epidermal growth factor, platelet-derived growth factor (PDGF), prolactin, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH agonists, growth hormone, growth hormone releasing factor, insulin, erythropoietin, somatostatin, glucagon, interleukin (including IL-2, IL-11, IL-12, etc.), interferon- α , interferon- β , interferon- γ , gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), parathyroid hormone (PTH), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), heparinase, vascular endothelial growth factor (VEGF), bone morphogenic protein (BMP), hANP, glucagon-like peptide (GLP-1), renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidine, gramicidins, cyclosporins, enzymes, cytokines, antibodies, vaccines, antibiotics, antibodies, glycoproteins, and combinations thereof.

No new matter has been added by virtue of these amendments.